Plavix gets US "boxed warning" about poor metabolisers
15 March 2010
Nancy Faigen
Bristol-Myers Squibb and
Sanofi-Aventis have added a "boxed warning" to the US label for the blockbuster blood thinner Plavix (clopidogrel), in order to warn about the diminished effectiveness of the drug in patients with a certain variant of the CYP2C1P liver enzyme leading to reduced formation of...
Please Login to read the full article.
15 March 2010
Nancy Faigen
Please Login to read the full article.
RELATED CONTENT
NEWS
- AstraZeneca heartened by US FDA nod to antiplatelet medicine Brilinta
- US FDA panel rejects BMS/AstraZeneca diabetes drug on cancer, liver injury concerns
- J&J's Xarelto wins US FDA OK for stroke, embolism prevention in afib
- EU approves InterMune "blockbuster" Esbriet; may face challenge from BI's 1120
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
